Shawn E. Lupold, Ph.D.
Affiliations: | 2001 | Johns Hopkins University, Baltimore, MD |
Area:
Pharmacology, Molecular Biology, BiochemistryGoogle:
"Shawn Lupold"Mean distance: 11375.1
Parents
Sign in to add mentor| Donald S. Coffey | grad student | 2001 | Johns Hopkins | |
| (Developing RNA aptamers for binding cell surface targets on prostate cancer cells.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Graham MK, Wang R, Chikarmane R, et al. (2023) Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer. Biorxiv : the Preprint Server For Biology |
| Lupold SE, Isaacs WB, Luo J. (2023) Aggravated Androgen Receptor Activity in Otherwise Indolent Prostate Cancer. European Urology |
| Kurozumi A, Lupold SE. (2021) Alternative polyadenylation: An untapped source for prostate cancer biomarkers and therapeutic targets? Asian Journal of Urology. 8: 407-415 |
| Mishra A, Zennami K, Velarde E, et al. (2021) Longitudinal measurement of subcutaneous and intratibial human prostate cancer xenograft growth and response to ionizing radiation by plasma Alu and LINE-1 ctDNA: A comparison to standard methods. The Prostate |
| Huang CT, Guo X, Bařinka C, et al. (2020) Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy. Molecular Pharmaceutics |
| Hapuarachchige S, Huang CT, Donnelly MC, et al. (2019) Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer. Molecular Pharmaceutics |
| Kurozumi A, Lupold SE. (2019) New functions assigned to a microRNA with genetic links to prostate cancer risk. Annals of Translational Medicine. 7: S193 |
| Fletcher CE, Sulpice E, Combe S, et al. (2019) Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. Oncogene |
| Zennami K, Rafiqi F, Liao R, et al. (2019) Abstract 4501: Loss of miR-21 delays myc-driven prostate cancer progression in the hi-myc transgenic mouse model Cancer Research. 79: 4501-4501 |
| Imada EL, Sanchez DF, Matam T, et al. (2019) Abstract 908: Comprehensive analysis of alternative polyadenylation across cancer phenotypes Cancer Research. 79: 908-908 |